MedTrace Logo

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

NCT05830539 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-05-02

No results posted yet for this study

Summary

This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

IN10018+PLD

IN10018 orally once daily; PLD 40mg/m2, Q4W

DRUG

IN10018+PLD+Toripalimab

IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Sponsors & Collaborators

  • InxMed (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lingying WU · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Xichun Hu · Fudan University

  • Dongmei Ji · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2024-08-31
Completion
2024-11-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05830539 on ClinicalTrials.gov